摘要目的:研究阿奇霉素联合斯奇康注射液对支气管哮喘的疗效及对髓系抑制性细胞(Myeloid-derived suppressor cells,MDSCs MDSCs)、血清免疫球蛋白E(immunoglobulin E IgE)、 嗜酸细胞活化趋化因子(eosinophil activated chemotactic factor eotaxin)的影响。方法:选取2017年3月至2018年4月我院的80例支气管哮喘患者。按照简单随机数表法分为观察组(42例)和对照组(38例),对照组采用斯奇康注射液治疗,观察组在对照组的基础上,采用阿奇霉素治疗。观察两组患者治疗疗效,临床症状消失时间,治疗前后肺功能指标(1s用力呼气量(forced expiratory volume in one second FEV1)、最大呼气流量(peak expiratory flow ,PEF)、第1秒用力呼气容积占用力肺活量百分比(forced expiratory volume in the first second is the percentage of forced vital capacity FEV1/FVC),MDSCs、IgE、Eotaxin水平。结果:治疗后,总有效率显著高于对照组[95.23%(40/42)vs73.68%(28/38)](P<0.05);临床症状消失时间均显著低于对照组[(2.98±0.87)d vs(6.90±1.32)d,(2.07±0.60)d vs(5.10±0.90)d,(3.97±1.02)d vs(6.70±1.58)d](P<0.05);FEV1、FEV1/FVC、PEF水平均高于对照组[(3.02±0.78)L vs(2.47±0.50)L,(88.38±20.47)% vs(79.59±15.38)%,(7.32±1.90)% vs(6.37±1.51)%](P<0.05);MDSCs、IgE、Eotaxin水平均低于对照组[(0.85±0.21)% vs(2.76±0.20)%,(78.19±14.02)% vs(91.45±17.71)% ,(0.07±0.02)% vs(0.19±0.04)% ](P<0.05)。结论:阿奇霉素联合斯奇康注射液对支气管哮喘的疗效显著,能够改善患者临床症状,抑制炎症释放,降低MDSCs、IgE、Eotaxin的水平,可作为治疗支气管炎哮喘的可靠方法。
Abstract：Objective: To study the effect of Azithromycin combined with Skikang injection on bronchial asthma and its effects on Myeloid-derived suppressor cells (MDSCs), serum immunoglobulin E IgE and eosinophil activated chemotactic factor Eotaxin. Methods: 102 patients of Bronchitis asthma who received therapy from March 2017 to April 2018 in our hospital were selected as research objects. According to simplerandom number table, those patients were divided into the observation group (n=42) and the control group (n=38). The control group was treated with Skikang injection, while the observation group was treated with azithromycin on the basis of the control group. The curative effect, disappearance time of clinical symptoms, pulmonary function indexes (forced expiratory volume in one second, maximum expiratory volume in the first second, percentage of forced expiratory volume in the first second, MDSCs, IgE and Eotaxin levels) were observed before and after treatment. Results: After treatment, the total effective rate of observation group was statistically higher than that in the control group [95.23%(40/42)vs 73.68%(28/38)] (P<0.05); The time of disappearance of clinical symptoms was significantly lower than that of the control group [(2.98±0.87)d vs (6.90±1.32)d,(2.07±0.60)d vs(5.10±0.90)d,(3.97±1.02)d vs(6.70±1.58)d](P<0.05); FEV1、FEV1/FVC、PEF were higher than those of the control group [(3.02±0.78)L vs(2.47±0.50)L,(88.38±20.47)% vs(79.59±15.38)%, (7.32±1.90)% vs (6.37±1.51)%](P<0.05); The levels of FEV1, FEV1/FVC and PEF were higher than those of the control group [(3.02±0.78)L vs(2.47±0.50)L,(88.38±20.47)% vs(79.59±15.38)%,(7.32±1.90)% vs(6.37±1.51)%](P<0.05); The levels of MDSCs, IgE and Eotaxin were lower than those of the control group [(0.85±0.21)% vs(2.76±0.20)%,(78.19±14.02)% vs (91.45±17.71)%, (0.07±0.02)% vs (0.19±0.04)% ](P<0.05). Conclusion: Azithromycin combined with cichikang injection has a significant effect on bronchitis asthma. It can improve the clinical symptoms, inhibit the release of inflammation and reduce the level of MDSCs, IgE and Eotaxin. It can be used as a reliable method to treat bronchitis.
夏魁, 闫妍. 阿奇霉素联合斯奇康注射液治疗支气管哮喘的疗效及对MDSCs IgE Eotaxin的影响[J]. 河北医学, 2019, 25(1): 59-62.
XIA kui, et al. Effect of Azithromycin combined with Siqikang Injection on Bronchitis Asthma and the Influences on MDSCs IgE and Eotaxin. HeBei Med, 2019, 25(1): 59-62.
[1] Spyroglou II, Spck G, Rigas AG, et al. Evaluation of Bayesian classifiers in asthma exacerbation prediction after medication discontinuation[J].BMC Res Notes,2018,11(1):522. [2] 郑海丽,王清兰.甲基强的松龙联合孟鲁司特钠治疗毛细支气管炎的疗效观察[J].天津医药,2013,41(03):263~264. [3] Uong A, Brandwein A, Crilly C, et al.Pleth Variability Index to Assess Course of Illness in Children with Asthma[J].Emerg Med,2018,55(2):179~184. [4] Kowalczyk A, Krogulska A.Usefulness of measurement of nitric oxide in exhaled air in diagnostics and treatment of allergic rhinitis and asthma in children and adolescents[J].Dev Period Med,2018,22(2):135~143. [5] 张海邻,吕芳芳.病毒性细支气管炎与哮喘相关性研究进展[J].中国实用儿科杂志,2017,32(12):895~900. [6] Kuiper IN, Svanes C, Benediktsdottir B,et al.Agreement in reporting of asthma by parents or offspring - the RHINESSA generation study[J].BMC Pulm Med,2018,18(1):122. [7] Jesus JPV, Lima-Matos AS, Almeida PCA, et al.Obesity and asthma: clinical and laboratory characterization of a common combination[J].Bras PneumoL,2018,44(3):207~212. [8] 罗炜,杨超培,王慧,等.诱导痰MUC5AC在嗜酸粒细胞性支气管炎和支气管哮喘患者中的差异分析[J].重庆医学,2016,45(11):1560~1562. [9] Turner SW, Murray C, Thomas M, et al.Applying UK real-world primary care data to predict asthma attacks in 3776 well-characterised children: a retrospective cohort study[J].NPJ Prim Care Respir Med,2018,28(1):28.
2019, Vol. 25 
冀公网安备13080202000786号